US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANI Pharmaceuticals

67.52

-0.7700-1.13%

Post-market: 67.520.00000.00%18:30 EDT

Volume:698.16K

Turnover:46.74M

Market Cap:1.47B

PE:-147.97

High:68.40

Open:66.02

Low:65.13

Close:68.29

Loading ...

Overview Company News Filings

ANI Pharmaceuticals price target raised to $62 from $60 at Truist

Truist Raises Price Target on ANI Pharmaceuticals to $62 From $60, Keeps Hold Rating

MT Newswires Live

ANI Pharmaceuticals Inc : Truist Securities Raises Target Price to $62 From $60

THOMSON REUTERS

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B

Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva

AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Simply Wall St.

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study

JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug

ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ANIP/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANIP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANIP\",,,,,undefined,":{"symbol":"ANIP","market":"US","secType":"STK","nameCN":"ANI Pharmaceuticals","latestPrice":67.52,"timestamp":1743796800000,"preClose":68.29,"halted":0,"volume":698163,"hourTrading":{"tag":"盘后","latestPrice":67.52,"preClose":67.52,"latestTime":"18:30 EDT","volume":5551,"amount":374782.93,"timestamp":1743805813557},"delay":0,"floatShares":16742600,"shares":21773510,"eps":-0.456324,"marketStatus":"Market Closed","change":-0.77,"latestTime":"04-04 16:00:00 EDT","open":66.02,"high":68.4,"low":65.13,"amount":46741377.52167,"amplitude":0.047884,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.456324,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1064980800000,"exchange":"NASDAQ","adjPreClose":68.29,"preHourTrading":{"tag":"盘前","latestPrice":66.6,"preClose":68.29,"latestTime":"09:29 EDT","volume":509,"amount":34379.868005,"timestamp":1743773355118},"postHourTrading":{"tag":"盘后","latestPrice":67.52,"preClose":67.52,"latestTime":"18:30 EDT","volume":5551,"amount":374782.93,"timestamp":1743805813557},"volumeRatio":1.9599626519368698,"impliedVol":0.6354,"impliedVolPercentile":0.9562},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANIP\",,,,,undefined,":{"symbol":"ANIP","floatShares":16742600,"roa":"0.84%","roe":"-4.18%","lyrEps":0.859674,"volumeRatio":1.9599626519368698,"shares":21773510,"dividePrice":0,"high":68.4,"amplitude":0.047884,"preClose":68.29,"low":65.13,"week52Low":52.5,"pbRate":"3.64","psRate":"2.39","week52High":70,"institutionHeld":0.9147,"latestPrice":67.52,"eps":-0.456324,"divideRate":0,"volume":698163,"delay":0,"ttmEps":-0.456324,"open":66.02,"prevYearClose":55.28,"prevWeekClose":67.61,"prevMonthClose":66.95,"prevQuarterClose":66.95,"fiveDayClose":67.61,"twentyDayClose":60.62,"sixtyDayClose":54.38},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANIP\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2477334402","title":"ANI Pharmaceuticals price target raised to $62 from $60 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2477334402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477334402?lang=en_us&edition=fundamental","pubTime":"2024-10-22 21:20","pubTimestamp":1729603211,"startTime":"0","endTime":"0","summary":"Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $62 from $60 and keeps a Hold rating on the shares as part of a broader rese...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ani-pharmaceuticals-price-target-raised-to-62-from-60-at-truist?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ani-pharmaceuticals-price-target-raised-to-62-from-60-at-truist?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANIP"],"gpt_icon":0},{"id":"2477874323","title":"Truist Raises Price Target on ANI Pharmaceuticals to $62 From $60, Keeps Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2477874323","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477874323?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:25","pubTimestamp":1729596335,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals (ANIP) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $60 to $94.(MT Newswires covers equity, commodity and eco","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANIP"],"gpt_icon":0},{"id":"2477382937","title":"ANI Pharmaceuticals Inc : Truist Securities Raises Target Price to $62  From $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2477382937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477382937?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:09","pubTimestamp":1729595368,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nFWN3LY0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANIP"],"gpt_icon":0},{"id":"2477651891","title":"NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B","url":"https://stock-news.laohu8.com/highlight/detail?id=2477651891","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477651891?lang=en_us&edition=fundamental","pubTime":"2024-10-21 23:52","pubTimestamp":1729525920,"startTime":"0","endTime":"0","summary":"Novo NordiskNVO announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years or older living with haemophilia A or B with inhibitors.Novo Nordisk’s Alhemo is a monoclonal antibody that blocks the TFPI, a protein that prevents blood clotting. By inhibiting TFPI, Alhemo promotes thrombin production, aiding blood clotting and stopping bleeding even in the absence/deficiency of other clotting factors. This enables Alhemo to promote clot formation even in the presence of inhibitors.The drug is already approved in Australia and Switzerland for treating adolescents and adults  with hemophilia A or B with inhibitors. NVO also markets Alhemo in Japan to treat the same patient population  and is used for routine prophylaxis to reduce or prevent bleeding episodes.Year to date, shares of Novo Nordisk have ga","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvos-alhemo-gets-positive-chmp-155200060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU2065171311.SGD","NVO","BK4139","LU2065171402.SGD","LU2065170008.USD","LU2065169927.USD","LU1093756325.SGD","ANIP","BK4532","ALNY","BK4156","LU0154236417.USD","BK4588","BK4548","FOLD","BK4087","IE00BZ1G4Q59.USD","CHMP","BK4007","IE00BKVL7J92.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2477671428","title":"Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2477671428","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477671428?lang=en_us&edition=fundamental","pubTime":"2024-10-21 21:40","pubTimestamp":1729518016,"startTime":"0","endTime":"0","summary":"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.One company value investors might notice is ANI Pharmaceuticals . ANIP is currently holding a Zacks Rank of #1  and a Value grade of A.These figures are just a handful of the metrics value investors tend to look at, but they help show that ANI Pharmaceuticals is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, ANIP feels like a great value stock at the moment.ANI Pharmaceuticals, Inc.  : Free Stock Analysis Report","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gUf3JPAiwp3PVjuDKftvaA--~B/aD04NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gUf3JPAiwp3PVjuDKftvaA--~B/aD04NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/value-investors-buy-ani-pharmaceuticals-134016039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ISBC","BK4007","ANIP","BK4211"],"gpt_icon":0},{"id":"2476529592","title":"Sage Therapeutics to Reduce Workforce by 33%, Stock Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2476529592","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476529592?lang=en_us&edition=fundamental","pubTime":"2024-10-19 00:12","pubTimestamp":1729267920,"startTime":"0","endTime":"0","summary":"Sage Therapeutics, Inc. SAGE announced a strategic reorganization and a portfolio reprioritization plan to support its ongoing business operations.As part of this strategic reorganization, SAGE is looking to reduce its current workforce by 33% and implement changes in the leadership team. Shares of the company were down 4.3% in after-hours trading on Thursday, following the announcement of the news.Owing to this reorganization, the company expects to record a non-recurring charge of around $26-$28 million in the fourth quarter of 2024. The restructuring process is likely to extend the company’s cash runway in the near future and support the long-term growth of its business.As part of the reprioritization, SAGE will focus on the commercialization of its depression drug Zurzuvae , which is marketed in partnership with drug giant, Biogen BIIB.Sage Therapeutics will also focus on its neuropsychiatric candidate, dalzanemdor , which is being evaluated in various mid-to-late-stage studies as ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-reduce-workforce-33-161200239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MCI","LU0943347566.SGD","BK4007","IE00BZ1G4Q59.USD","LU1496350171.SGD","LU1496350502.SGD","IE00B1XK9C88.USD","BIIB","BK4532","LU0820561818.USD","VYGR","LU0689472784.USD","SG9999001440.SGD","LU1169589451.USD","LU1169590202.USD","LU1674673691.USD","LU0079474960.USD","LU1551013425.SGD","LU0889565916.HKD","LU0234572021.USD","BK4533","PPD","BK4588","BK4585","LU2756315664.SGD","BK4504","LU1674673428.USD","LU0234570918.USD","BK4550","IE00BWXC8680.SGD","HD","IE00BSNM7G36.USD","LU1778281490.HKD","LU1551013342.USD","PD","ANIP","BK4530","BK4121","IE00B19Z9Z06.USD","BK4561","SAGE","LU2756315318.SGD","BK4139","BK4581","LU1093756168.USD","IE00B894F039.SGD","CRL","LU0942090050.USD","LU1162221912.USD","LU1914381329.SGD"],"gpt_icon":0},{"id":"2476265594","title":"FOLD Stock Rises on Settling Galafold Patent Dispute With Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=2476265594","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476265594?lang=en_us&edition=fundamental","pubTime":"2024-10-18 22:33","pubTimestamp":1729261980,"startTime":"0","endTime":"0","summary":"Amicus TherapeuticsFOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold  123 mg capsules before the related patents expired. The stock jumped 14% on Thursday as investors cheered the dispute settlement with TEVA.Galafold, Amicus’ lead marketed drug, is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants.Under the terms of the agreement, Amicus will grant Teva a license to sell its generic version of Galafold in the United States starting Jan. 30, 2037, pending FDA approval and subject to the fulfillment of certain customary conditions. The agreement ends all ongoing litigation between Amicus and Teva concerning Galafold patents in the U.S. District Court for Delaware. However, the litigation wil","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fold-stock-rises-settling-galafold-143300827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4557","BK4139","TEVA","BK4588","BK4007","ANIP","BK4548","FOLD","LU2065169927.USD","BK4566","BK4585","LU2065171311.SGD","LU2065171402.SGD","BK4559","BK4584","ALNY","LU2065170008.USD"],"gpt_icon":0},{"id":"2476252831","title":"AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev","url":"https://stock-news.laohu8.com/highlight/detail?id=2476252831","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476252831?lang=en_us&edition=fundamental","pubTime":"2024-10-18 21:04","pubTimestamp":1729256640,"startTime":"0","endTime":"0","summary":"AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease . The drug will be marketed under the trade name Vyalev.Vyalev is a solution of carbidopa  and levodopa  prodrugs, which are the standard of care for PD patients. Prodrugs aremedications that become active once they enter the body. The drug has been designed to offer continuous subcutaneous delivery of CD/LD prodrugs through a pump device and improve patient experience.Following this approval, Vyalev has become the first and only 24-hour continuous infusion of levodopa-based therapy to treat the given indication. The drug has already been launched for similar use in 34 countries, including Europe and Japan, where it is marketed under the trade name Produodopa.Per management, \"On\" time is cited as the period when symptoms are well controlled without dyskinesia or involuntary movements. The goal of PD patients and phys","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-secures-fda-approval-parkinsons-130400593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","LU0310800379.SGD","BK4533","BK4588","IE0009355771.USD","BK4559","ABBV","IE00B42XCP33.USD","LU0943347566.SGD","BK4007","IE00B3PB1722.GBP","LU0029864427.USD","LU0256863902.USD","LU0882574055.USD","LU0861579265.USD","LU0203347892.USD","IE00B4R5TH58.HKD","BK4566","IE00BGHQF631.EUR","LU0965509010.AUD","LU0985320562.USD","CSTL","IE00BVYPNV92.GBP","LU0158827948.USD","LU0738911758.USD","LU0949170772.SGD","LU0203345920.USD","LU0456855351.SGD","LU0234570918.USD","LU0310799852.SGD","LU0256863811.USD","IE00BSNM7G36.USD","IE00BDGV0183.EUR","LD","LU0170899867.USD","LU0689472784.USD","LU0211327993.USD","BK4139","LU0795875086.SGD","IE0004445239.USD","LU0198837287.USD","LU0545039389.USD","IE00BFTCPJ56.SGD","LU0708994859.HKD","ANIP","CD","ALNY","LU0965509101.SGD","BK4585","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2476831814","title":"SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2476831814","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476831814?lang=en_us&edition=fundamental","pubTime":"2024-10-18 00:01","pubTimestamp":1729180860,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that it has entered into an agreement with France-based cancer biotech Orano Med to jointly develop next-generation radioligand therapies for treating rare cancers.Radioligand therapy is a type of precision cancer treatment that combines a targeting compound  with a therapeutic radioisotope .Per the agreement, both Sanofi and Orano Med will design a new entity and focus on the clinical development of next-generation radioligand therapies  based on lead-212  alpha-emitting isotopes. The new entity will operate under the brand of Orano Med.Year to date, shares of Sanofi have increased 9.5% compared with the industry’s rise of 20.6%.In the past 60 days, estimates for Elevation Oncology’s 2024 loss per share have narrowed from 86 cents to 82 cents. Loss per share estimates for 2025 have narrowed from 90 cents to 86 cents. Year to date, shares of ELEV have increased 2.8%.ELEV’s earnings beat estimates in three of the trailing four quarters while missing on the remaining","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sny-inks-deal-orano-med-160100588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYGR","SNY","BK4007","BK4539","BK4588","IE00BFXG1179.USD","TAT","BK4139","BK4585","ELEV","ANIP"],"gpt_icon":0},{"id":"2476704381","title":"Are Medical Stocks Lagging  Alnylam Pharmaceuticals (ALNY) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2476704381","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476704381?lang=en_us&edition=fundamental","pubTime":"2024-10-17 21:40","pubTimestamp":1729172411,"startTime":"0","endTime":"0","summary":"Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.Alnylam Pharmaceuticals is one of 1025 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Alnylam Pharmaceuticals is currently sporting a Zacks Rank of #2 .Another stock in the Medical sector, ANI Pharmaceuticals , has outperformed the sector so far this yea","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hYDVEF34jJNULlluFRTwjg--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hYDVEF34jJNULlluFRTwjg--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-alnylam-pharmaceuticals-134011724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4548","BK4139","ANIP","ALNY","BK4007","BK4588"],"gpt_icon":0},{"id":"2476435170","title":"Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2476435170","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476435170?lang=en_us&edition=fundamental","pubTime":"2024-10-17 21:34","pubTimestamp":1729172040,"startTime":"0","endTime":"0","summary":"Please note that Alnylam already markets vutrisiran in the EU under the brand name Amvuttra for treating hereditary transthyretin-mediated  amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.The application seeking approval for vutrisiran to treat ATTR-CM is supported by positiveresults from ALNY’s pivotal phase III HELIOS-B study, which met all primary and secondary endpoints across both the overall and monotherapy populations, each with statistical significance.Year to date, shares of Alnylam have gained 57% against the industry’s 1% decline.Per the data readout, vutrisiran reduced mortality and cardiovascular events while improving functional capacity , quality of life , and heart failure symptoms and severity  in ATTR-CM patients.Additionally, the safety profile of vutrisiran in the HELIOS-B study was consistent with its known profile for treating hATTR amyloidosis with polyneuropathy in adults. In the late-stage study, the rates of adverse events, including those","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-stock-cardiomyopathy-drug-regulatory-133400977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIP","LU0211331839.USD","NVS","IE00B2B36J28.USD","BK4548","BK4007","IE00B4R5TH58.HKD","LU2065171311.SGD","BK4156","IE0009355771.USD","BK4585","BK4588","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","ALNY","IE00BFTCPJ56.SGD","LU2065169927.USD","LU2065170008.USD","BK4578","BK4532","BK4139","LU2065171402.SGD","FOLD"],"gpt_icon":0},{"id":"2476413951","title":"ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?","url":"https://stock-news.laohu8.com/highlight/detail?id=2476413951","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476413951?lang=en_us&edition=fundamental","pubTime":"2024-10-17 19:05","pubTimestamp":1729163132,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals  has had a great run on the share market with its stock up by a significant 8.3% over the last week. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current share price momentum can be maintained. In this article, we decided to focus on ANI Pharmaceuticals'  ROE.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.We then compared ANI Pharmaceuticals' performance with the industry and found that the company has shrunk its earnings at a slower rate than the industry earnings which has seen its earnings shrink by 0.3% in the same 5-year period. While this is not particularly good, its not particularly bad either.ANI Pharmaceuticals doesn't pay any regular dividends, meaning that the company is keeping all o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-pharmaceuticals-inc-nasdaq-anip-110532858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","QLD","MNQmain","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","BK4007","IE00B64PRP62.GBP","BK4112","LU2210150020.SGD","SQQQ","NQmain","BK4585","LU2095319765.USD","IE00BGHQF748.EUR",".IXIC","QID","PSQ","TQQQ","NDAQ","ANIP"],"gpt_icon":1},{"id":"2476945329","title":"IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2476945329","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476945329?lang=en_us&edition=fundamental","pubTime":"2024-10-16 22:24","pubTimestamp":1729088640,"startTime":"0","endTime":"0","summary":"Immuneering Corporation IMRX announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up 15.5% on Oct. 15 following the announcement of the news.The FDA grants Orphan Drug Designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The Orphan Drug Designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies as well as exemptions from certain FDA application fees.IMM-1-104 was earlier granted the FDA’s Fast Track designation in the United States for the treatment of first- and second-line pancreatic cancer.Year to date, shares of Immuneering have plunged 68.6% compared with the industry’s decrease of 1.8%.Last month, the company announced positive early response data from the first five patients of an ongoin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imrx-stock-fdas-orphan-drug-142400084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","ALNY","IMRX","VYGR","BK4007","BK4588","BK4139","BK4563","BK4539","ANIP","BK4585"],"gpt_icon":0},{"id":"2476945028","title":"MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2476945028","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476945028?lang=en_us&edition=fundamental","pubTime":"2024-10-16 22:19","pubTimestamp":1729088340,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease  metits primary study objective of safetyand tolerability. The stock soared 14.9% in response to the news.MGTX’s PD Gene Therapy Candidate Betters Sham Treatment. The MGT-GAD-025 study of AAV-GAD for PD demonstrated significant and clinically meaningful improvements from baseline for key efficacy endpoints after 26 weeks of treatment.The investigational gene therapy was also found to be generally safe and overall well-tolerated. No serious, AAV-GAD treatment-related adverse events wereobserved.AAV-GAD has a novel mechanism of action that aims to correct the aberrant circuitry that results from the depletion of dopamine in the brain of idiopathic PD patients as the disease progresses. Using the company's proprietary delivery instrument, AAV-GAD is administered as a one-time infusion into the subthalamic nucleus, a key regulator of the circuits responsible for normal m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x7AJ0AkRL_CYuqXFyPb2BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x7AJ0AkRL_CYuqXFyPb2BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mgtx-stock-upbeat-efficacy-data-141900975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065169927.USD","LU2065171402.SGD","BK4023","BK4585","BK4588","LU1169590202.USD","FOLD","LU2065171311.SGD","PD","BK4139","BK4548","ALNY","ANIP","LU2065170008.USD","MGTX","BK4007","LU1169589451.USD"],"gpt_icon":0},{"id":"2475594861","title":"JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2475594861","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475594861?lang=en_us&edition=fundamental","pubTime":"2024-10-16 21:53","pubTimestamp":1729086780,"startTime":"0","endTime":"0","summary":"Shares of Jazz Pharmaceuticals JAZZ rose nearly 6% on Tuesday after it reported positive top-line results from the phase III IMfortestudy, which evaluated Zepzelca , combined with Roche’s RHHBY Tecentriq , in patients with extensive-stage small cell lung cancer .The Roche-sponsored IMfortestudy achieved statistically significant improvement in the primary endpoints of overall survival and progression-free survival. Treatment with the Zepzelca-Tecentriq combination outpaced Tecentriq alone when used as a first-line maintenance treatment for adults with ES-SCLC, following induction therapy with chemotherapy, Tecentriq and etoposide. The combination therapy was also well-tolerated in study participants, with no new safety signal.Based on the above results, Jazz intends to submit a regulatory filing in first-half 2025 seeking approval for Zepzelca plus Roche’s Tecentriq as a first-line maintenance treatment for ES-SCLC. It also plans to present the IMforte results at a future medical meeti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-stock-soars-combo-therapy-135300113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","BK4532","ANIP","LU0320765992.SGD","03165","BK4007","BK4588","BK4139","BK4585","RHHBY","BK4548","LU0109394709.USD","LU0889565916.HKD","JAZZ","ALNY"],"gpt_icon":0},{"id":"2475228654","title":"Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?","url":"https://stock-news.laohu8.com/highlight/detail?id=2475228654","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475228654?lang=en_us&edition=fundamental","pubTime":"2024-10-16 00:10","pubTimestamp":1729008616,"startTime":"0","endTime":"0","summary":"Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report?It is worth considering ANI Pharmaceuticals , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this drugmaker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 16.57%, on average, in the last two quarters.For the last reported quarter, ANI came out with earnings of $1.02 per share versus the Zacks Consensus Estimate of $0.93 per share, representing a surprise of 9.68%. For the previous quarter, the company was expected to post earnings of $0.98 per share and it actually produced earnings of $1.21 per share, delivering a surprise of 23.47%.For ANI, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP , it's a great indicator of a future earnings beat, especially w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xMhOxlfdhVA7Ts3pP3IHyA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xMhOxlfdhVA7Ts3pP3IHyA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-anip-beat-estimates-again-161016231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIP"],"gpt_icon":0},{"id":"2475182657","title":"VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2475182657","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475182657?lang=en_us&edition=fundamental","pubTime":"2024-10-15 23:51","pubTimestamp":1729007460,"startTime":"0","endTime":"0","summary":"Vanda Pharmaceuticals Inc. VNDA announced that its board of directors has unanimously rejected a second acquisition bid by United Kingdom-based Cycle Group Holdings Ltd.  wherein the latter proposed to acquire VNDA for $8.00 per share in cash.Shares of Vanda were up 8.3% on Oct 14 following the announcement of the news.Vanda received the second takeover proposal from Cycle Group on Sep 23, 2024.Per management, the second unsolicited, non-binding acquisition proposal was economically identical to Cycle Group's previous takeover interest that was received by the company in May.After thoroughly reviewing the second takeover bid, Vanda’s board of directors concluded that the latest proposal substantially undervalues the company and is not in the best interests of the company and its shareholders.Vanda shareholders will not have to take any immediate action related to the second unsolicited takeover proposal from the Cycle Group.Year to date, shares of Vanda have rallied 14% against the ind","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vnda-rejects-second-takeover-bid-155100524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JNJ","BK4532","LU0320765646.SGD","IE0002141913.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","CRL","LU0114720955.EUR","IE00BGHQF631.EUR","BK4504","IE0034235303.USD","IE00B19Z3581.USD","LU1066051498.USD","BK4121","VNDA","LU0345770993.USD","LU1066051225.USD","LU1032955483.USD","IE00B3PB1722.GBP","BK4592","LU1032466523.USD","BK4139","LU0234570918.USD","BK4581","LU0203345920.USD","LU0203347892.USD","IE00BJT1NW94.SGD","ALNY","ANIP","LU0795875086.SGD","IE00B2B36J28.USD","IE00B42XCP33.USD","LU0882574055.USD","IE00B7SZLL34.SGD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU0466842654.USD","LU1023059063.AUD","LU0345769631.USD","LU0098860793.USD","LU0912757837.SGD","LU1196500208.SGD","LU0792757196.USD","IE00BVYPNV92.GBP","LU1221951046.USD","LU0889566641.SGD","LU0795875169.SGD","IE00BVYPNW00.USD","BK4550","BK4530"],"gpt_icon":0},{"id":"2475631288","title":"Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475631288","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475631288?lang=en_us&edition=fundamental","pubTime":"2024-10-15 22:13","pubTimestamp":1729001580,"startTime":"0","endTime":"0","summary":"The cash consideration represents a 77% premium over the 30-day volume-weighted average price of Longboard's common stock as of Sept. 30, 2024. The transaction has been unanimously approved by the board of directors of both companies and is set to close in the fourth quarter of 2024, subject to the fulfillment of certain customary and regulatory conditions. Lundbeck expects to finance the transaction through existing cash resources and bank financing.Longboard is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurological disorders. Its lead candidate, bexicaserin, is currently undergoing phase III development and has shown promise in reducing seizures. This next-generation superagonist targets 5-HT2C receptors, which may enable bexicaserin to offer a unique and potentially best-in-class treatment profile.Buyout of LBPH to Enhance Lundbeck’s Neuroscience Pipeline. Lundbeck's acquisition of Longboard is a strategic move to build a neuro-rare","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/P_YBJxpMtPac37tw4WAE2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9752031dabc84079fccfebaf63c9eff9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/P_YBJxpMtPac37tw4WAE2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9752031dabc84079fccfebaf63c9eff9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/longboard-set-acquired-lundbeck-2-141300770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALNY","BK4548","ANIP","BK4588","BK4007","BK4139","BK4585","XENE","LBPH"],"gpt_icon":0},{"id":"2475682229","title":"RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2475682229","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475682229?lang=en_us&edition=fundamental","pubTime":"2024-10-15 21:01","pubTimestamp":1728997260,"startTime":"0","endTime":"0","summary":"Shares of Repare Therapeutics RPTX gained 8% on Monday after it announced dosing the first patient in an early-stage study evaluating the combination regimen of its Polθ ATPase inhibitor, RP-3467, and AstraZeneca’s AZN Lynparza , a leading PARP inhibitor, to treat several advanced solid tumors.Per Repare, RP-3467 has demonstrated highly significant preclinical results where treatment with the candidate in combination with AstraZeneca’s Lynparza led to complete and durable tumor regressions with no additive toxicities. Based on such encouraging results, RPTX believes that the combination has the potential to meaningfully improve patient outcomes by mitigating PARP inhibitor resistance, which represents a substantial area of unmet medical need.Additionally, previously reported data from Repare demonstrated the potential of RP-3467 to enhance efficacy and reduce toxicity when combined with radioligand therapy and chemotherapy-based antibody-drug conjugates. The company anticipates further","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rptx-stock-dosing-begins-solid-130100708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0889565916.HKD","LU2417539215.USD","RPTX","ALNY","LU0320765992.SGD","AZN","ANIP","BK4568","BK4548","LU2462157665.USD","LU2456880835.USD","BK4588","BK4585","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD","BK4007"],"gpt_icon":0},{"id":"2474048549","title":"ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2474048549","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474048549?lang=en_us&edition=fundamental","pubTime":"2024-10-12 01:40","pubTimestamp":1728668429,"startTime":"0","endTime":"0","summary":"Piper Sandler has initiated coverage on ANI Pharmaceuticals ,an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines.Cortrophin gel sales more than doubled to $49.2 million in the second quarter of 2024, driven primarily by increased volume. The company raised the fiscal year 2024 Cortrophin gel outlook from $170 million-$180 million to $185 million-$195 million.The FDA approved Cortrophin Gel in 2021, which covers several autoimmune diseases. At that time, there was only one other ACTH player, Mallinckrodt Plc’s  Acthar Gel. The company and the drug have been associated with payer challenges, negative attention associated with the Medicaid rebate-related litigation and eventual settlement, and pandemic-associated disruption.When ANI launched in the market, it identified significant promotion sensitivity linked to its relatively high-priced product, typically used after various more affordable immunomodulatory alternatives.The transaction mad","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ywZkMDagWmXD.N4QwLtCng--~B/aD01NzQ7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/b83c8a0d9a40bf4d657d5c4c3ce6eb59","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ywZkMDagWmXD.N4QwLtCng--~B/aD01NzQ7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/b83c8a0d9a40bf4d657d5c4c3ce6eb59"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-pharmaceuticals-shifts-focus-generics-174029506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ANIP","CVR","BK4161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":195}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANIP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-28","symbol":"ANIP","fiscalQuarterEnding":"2024/12","expectedEps":1.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740718800000,"reportTimeType":"pre","actualEps":1.35},{"market":"US","date":"2025-01-13","symbol":"ANIP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1736744400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-08","symbol":"ANIP","fiscalQuarterEnding":"2024/09","expectedEps":0.76,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":1.04},{"market":"US","date":"2024-08-06","symbol":"ANIP","fiscalQuarterEnding":"2024/06","expectedEps":0.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"pre","actualEps":0.72},{"market":"US","date":"2024-05-10","symbol":"ANIP","fiscalQuarterEnding":"2024/03","expectedEps":0.79,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":0.95}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANIP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANIP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.5,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1742011200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANIP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANIP","date":"2025-04-04","current":-74.873618,"percent":0.161501,"low":-311.184856,"twenty":-37.127584,"median":-15.916284,"eighty":33.489434,"high":97.86975,"avg":-34.4095,"sd":88.145289,"marketCap":1386809145},"quantilePoints":[{"date":"2020-04-09","current":92.224169,"twenty":21.531406,"median":49.390116,"eighty":175.320971,"marketCap":562014088},{"date":"2020-04-17","current":84.253938,"twenty":21.569236,"median":49.501086,"eighty":175.341115,"marketCap":513443500},{"date":"2020-04-24","current":84.512513,"twenty":21.639216,"median":49.740542,"eighty":175.341115,"marketCap":515019254},{"date":"2020-05-01","current":78.483131,"twenty":21.68665,"median":49.897003,"eighty":175.341115,"marketCap":478276200},{"date":"2020-05-08","current":-306.724064,"twenty":21.68665,"median":49.897003,"eighty":174.662929,"marketCap":418985071},{"date":"2020-05-15","current":-276.747541,"twenty":21.639216,"median":49.740542,"eighty":171.157853,"marketCap":378037141},{"date":"2020-05-22","current":-281.654412,"twenty":21.569236,"median":49.501086,"eighty":129.970868,"marketCap":384739927},{"date":"2020-05-29","current":-277.104405,"twenty":21.540251,"median":49.4105,"eighty":114.118791,"marketCap":378524617},{"date":"2020-06-05","current":-287.007363,"twenty":21.490641,"median":49.320114,"eighty":112.769329,"marketCap":392052058},{"date":"2020-06-12","current":-279.334801,"twenty":21.43174,"median":49.19183,"eighty":110.88517,"marketCap":381571338},{"date":"2020-06-19","current":-267.023015,"twenty":21.397336,"median":49.143393,"eighty":110.230911,"marketCap":364753438},{"date":"2020-06-26","current":-271.84067,"twenty":21.260922,"median":48.961869,"eighty":109.609404,"marketCap":371334355},{"date":"2020-07-02","current":-275.587735,"twenty":21.213916,"median":48.819209,"eighty":108.674596,"marketCap":376452846},{"date":"2020-07-10","current":-242.656217,"twenty":21.146728,"median":48.595145,"eighty":107.483212,"marketCap":331468393},{"date":"2020-07-17","current":-267.608014,"twenty":21.004704,"median":48.464447,"eighty":106.487144,"marketCap":365552547},{"date":"2020-07-24","current":-236.240042,"twenty":20.955588,"median":48.183479,"eighty":105.494518,"marketCap":322703897},{"date":"2020-07-31","current":-263.865245,"twenty":20.91187,"median":47.740116,"eighty":104.82867,"marketCap":360439924},{"date":"2020-08-07","current":-17.948035,"twenty":20.772397,"median":47.399928,"eighty":102.855769,"marketCap":364111791},{"date":"2020-08-14","current":-19.147723,"twenty":20.710873,"median":47.109625,"eighty":102.014304,"marketCap":388449853},{"date":"2020-08-21","current":-18.462187,"twenty":20.602327,"median":46.853471,"eighty":100.138989,"marketCap":374542389},{"date":"2020-08-28","current":-18.474007,"twenty":20.558652,"median":46.566876,"eighty":99.313001,"marketCap":374782173},{"date":"2020-09-04","current":-17.227041,"twenty":20.458555,"median":46.389314,"eighty":97.780868,"marketCap":349484975},{"date":"2020-09-11","current":-16.322843,"twenty":20.389015,"median":46.259964,"eighty":95.080791,"marketCap":331141510},{"date":"2020-09-18","current":-17.942125,"twenty":20.307358,"median":45.914271,"eighty":94.158771,"marketCap":363991899},{"date":"2020-09-25","current":-16.10418,"twenty":20.231122,"median":45.803098,"eighty":93.899855,"marketCap":326705509},{"date":"2020-10-02","current":-16.896092,"twenty":20.188569,"median":45.677543,"eighty":93.899855,"marketCap":342771027},{"date":"2020-10-09","current":-18.190337,"twenty":20.1016,"median":45.515812,"eighty":93.831974,"marketCap":369027360},{"date":"2020-10-16","current":-17.605267,"twenty":20.025882,"median":45.358477,"eighty":93.831974,"marketCap":357158059},{"date":"2020-10-23","current":-17.108845,"twenty":19.935944,"median":45.290838,"eighty":93.831974,"marketCap":347087137},{"date":"2020-10-30","current":-15.064057,"twenty":19.853111,"median":45.178762,"eighty":93.831974,"marketCap":305604529},{"date":"2020-11-06","current":-11.966257,"twenty":19.635625,"median":45.101076,"eighty":93.831974,"marketCap":284174674},{"date":"2020-11-13","current":-14.042294,"twenty":19.43091,"median":45.101076,"eighty":93.831974,"marketCap":333476401},{"date":"2020-11-20","current":-14.15342,"twenty":19.270511,"median":45.101076,"eighty":93.831974,"marketCap":336115423},{"date":"2020-11-27","current":-14.890893,"twenty":19.083542,"median":45.101076,"eighty":93.831974,"marketCap":353628931},{"date":"2020-12-04","current":-14.815125,"twenty":18.677139,"median":45.033423,"eighty":93.831974,"marketCap":351829598},{"date":"2020-12-11","current":-15.118197,"twenty":18.135705,"median":44.963168,"eighty":93.831974,"marketCap":359026931},{"date":"2020-12-18","current":-15.744543,"twenty":17.809673,"median":44.893709,"eighty":93.831974,"marketCap":373901418},{"date":"2020-12-24","current":-14.143318,"twenty":17.67856,"median":44.788392,"eighty":93.831974,"marketCap":335875512},{"date":"2020-12-31","current":-14.668641,"twenty":17.562123,"median":44.750872,"eighty":93.831974,"marketCap":348350888},{"date":"2021-01-08","current":-15.81526,"twenty":17.494531,"median":44.671419,"eighty":93.831974,"marketCap":375580795},{"date":"2021-01-15","current":-16.229457,"twenty":17.372674,"median":44.671419,"eighty":93.831974,"marketCap":385417150},{"date":"2021-01-22","current":-16.209252,"twenty":17.122322,"median":44.671419,"eighty":93.831974,"marketCap":384937327},{"date":"2021-01-29","current":-14.416082,"twenty":16.943136,"median":44.671419,"eighty":93.831974,"marketCap":342353111},{"date":"2021-02-05","current":-15.512189,"twenty":16.763257,"median":44.671419,"eighty":93.831974,"marketCap":368383463},{"date":"2021-02-12","current":-15.906181,"twenty":16.268593,"median":44.671419,"eighty":93.831974,"marketCap":377739995},{"date":"2021-02-19","current":-15.274783,"twenty":15.830659,"median":44.671419,"eighty":93.831974,"marketCap":362745552},{"date":"2021-02-26","current":-14.698948,"twenty":-12.119813,"median":44.671419,"eighty":93.831974,"marketCap":349070621},{"date":"2021-03-05","current":-14.900996,"twenty":-13.866513,"median":44.684665,"eighty":93.840828,"marketCap":353868843},{"date":"2021-03-12","current":-17.719586,"twenty":-14.185748,"median":44.684665,"eighty":93.840828,"marketCap":399541231},{"date":"2021-03-19","current":-18.809938,"twenty":-14.28172,"median":44.684665,"eighty":93.840828,"marketCap":424126483},{"date":"2021-03-26","current":-17.905878,"twenty":-14.478717,"median":44.671419,"eighty":93.831974,"marketCap":403741726},{"date":"2021-04-01","current":-18.645563,"twenty":-14.700969,"median":44.671419,"eighty":93.831974,"marketCap":420420163},{"date":"2021-04-09","current":-17.456587,"twenty":-14.79391,"median":44.684665,"eighty":93.840828,"marketCap":393611120},{"date":"2021-04-16","current":-18.727751,"twenty":-14.933323,"median":44.684665,"eighty":93.840828,"marketCap":422273323},{"date":"2021-04-23","current":-18.490979,"twenty":-15.018183,"median":44.619273,"eighty":93.840828,"marketCap":416934604},{"date":"2021-04-30","current":-18.67617,"twenty":-15.151534,"median":44.517552,"eighty":93.840828,"marketCap":421110277},{"date":"2021-05-07","current":-30.006302,"twenty":-15.294988,"median":44.482394,"eighty":93.840828,"marketCap":463627379},{"date":"2021-05-14","current":-27.254429,"twenty":-15.522291,"median":44.482394,"eighty":93.840828,"marketCap":421108184},{"date":"2021-05-21","current":-27.503186,"twenty":-15.637458,"median":44.482394,"eighty":93.840828,"marketCap":424951727},{"date":"2021-05-28","current":-26.7025,"twenty":-15.830414,"median":44.482394,"eighty":93.840828,"marketCap":412580323},{"date":"2021-06-04","current":-26.725821,"twenty":-15.90012,"median":44.482394,"eighty":93.840828,"marketCap":412940655},{"date":"2021-06-11","current":-27.091182,"twenty":-16.033471,"median":44.482394,"eighty":93.840828,"marketCap":418585859},{"date":"2021-06-18","current":-25.629735,"twenty":-16.113636,"median":44.482394,"eighty":93.840828,"marketCap":396005043},{"date":"2021-06-25","current":-25.684151,"twenty":-16.211273,"median":44.482394,"eighty":93.840828,"marketCap":396845818},{"date":"2021-07-02","current":-27.238882,"twenty":-16.280292,"median":44.482394,"eighty":93.840828,"marketCap":420867962},{"date":"2021-07-09","current":-25.917361,"twenty":-16.381941,"median":44.482394,"eighty":93.840828,"marketCap":400449140},{"date":"2021-07-16","current":-25.458715,"twenty":-16.61715,"median":44.482394,"eighty":93.840828,"marketCap":393362608},{"date":"2021-07-23","current":-25.754114,"twenty":-16.70107,"median":44.482394,"eighty":93.840828,"marketCap":397926815},{"date":"2021-07-30","current":-26.376006,"twenty":-16.867725,"median":44.482394,"eighty":93.840828,"marketCap":407535672},{"date":"2021-08-06","current":-23.241466,"twenty":-17.134848,"median":44.482394,"eighty":93.840828,"marketCap":400241286},{"date":"2021-08-13","current":-21.12541,"twenty":-17.212103,"median":44.482394,"eighty":93.840828,"marketCap":363800685},{"date":"2021-08-20","current":-19.656122,"twenty":-17.353092,"median":44.482394,"eighty":93.840828,"marketCap":338498075},{"date":"2021-08-27","current":-19.656122,"twenty":-17.522336,"median":44.482394,"eighty":93.840828,"marketCap":338498075},{"date":"2021-09-03","current":-20.738755,"twenty":-17.700637,"median":44.482394,"eighty":93.840828,"marketCap":357142104},{"date":"2021-09-10","current":-19.290557,"twenty":-17.899303,"median":44.482394,"eighty":93.840828,"marketCap":332202689},{"date":"2021-09-17","current":-20.30992,"twenty":-18.060321,"median":44.482394,"eighty":93.840828,"marketCap":349757131},{"date":"2021-09-24","current":-22.461126,"twenty":-18.091073,"median":44.482394,"eighty":93.840828,"marketCap":386803058},{"date":"2021-10-01","current":-23.60703,"twenty":-18.425232,"median":44.482394,"eighty":93.840828,"marketCap":406536672},{"date":"2021-10-08","current":-26.123801,"twenty":-18.468453,"median":44.482394,"eighty":93.840828,"marketCap":449877985},{"date":"2021-10-15","current":-27.093953,"twenty":-18.504447,"median":44.482394,"eighty":93.840828,"marketCap":466584972},{"date":"2021-10-22","current":-25.912899,"twenty":-18.647858,"median":44.482394,"eighty":93.840828,"marketCap":446246032},{"date":"2021-10-29","current":-26.278463,"twenty":-18.720372,"median":44.482394,"eighty":93.840828,"marketCap":452541418},{"date":"2021-11-05","current":-27.374652,"twenty":-18.921969,"median":44.482394,"eighty":93.840828,"marketCap":605034567},{"date":"2021-11-12","current":-24.93381,"twenty":-19.161127,"median":44.482394,"eighty":93.840828,"marketCap":551087062},{"date":"2021-11-19","current":-23.828316,"twenty":-19.298993,"median":44.482394,"eighty":93.840828,"marketCap":526653439},{"date":"2021-11-26","current":-22.312367,"twenty":-19.550771,"median":44.482394,"eighty":93.840828,"marketCap":493147926},{"date":"2021-12-03","current":-21.644692,"twenty":-19.661746,"median":44.482394,"eighty":93.840828,"marketCap":478390986},{"date":"2021-12-10","current":-23.926825,"twenty":-19.830468,"median":44.482394,"eighty":93.840828,"marketCap":528830693},{"date":"2021-12-17","current":-35.479789,"twenty":-20.340852,"median":44.482394,"eighty":93.840828,"marketCap":784174295},{"date":"2021-12-23","current":-38.555108,"twenty":-20.692356,"median":44.482394,"eighty":93.840828,"marketCap":852144996},{"date":"2021-12-31","current":-34.904113,"twenty":-21.292726,"median":44.482394,"eighty":93.840828,"marketCap":771450716},{"date":"2022-01-07","current":-33.23011,"twenty":-21.571117,"median":44.47091,"eighty":93.831974,"marketCap":734451886},{"date":"2022-01-14","current":-32.593837,"twenty":-22.321029,"median":44.47091,"eighty":93.831974,"marketCap":720388982},{"date":"2022-01-21","current":-31.056177,"twenty":-22.471872,"median":44.47091,"eighty":93.831974,"marketCap":686403632},{"date":"2022-01-28","current":-29.81393,"twenty":-23.061496,"median":44.47091,"eighty":93.831974,"marketCap":658947486},{"date":"2022-02-04","current":-29.064037,"twenty":-23.582662,"median":44.47091,"eighty":93.831974,"marketCap":642373350},{"date":"2022-02-11","current":-29.783632,"twenty":-23.857812,"median":44.47091,"eighty":93.831974,"marketCap":658277824},{"date":"2022-02-18","current":-28.336868,"twenty":-24.385441,"median":44.47091,"eighty":93.831974,"marketCap":626301460},{"date":"2022-02-25","current":-28.382316,"twenty":-24.728034,"median":44.47091,"eighty":93.831974,"marketCap":627305953},{"date":"2022-03-04","current":-27.473355,"twenty":-25.399635,"median":44.47091,"eighty":93.831974,"marketCap":607216091},{"date":"2022-03-11","current":-27.503654,"twenty":-25.579458,"median":44.47091,"eighty":93.831974,"marketCap":607885753},{"date":"2022-03-18","current":-10.584628,"twenty":-25.602756,"median":44.47091,"eighty":93.831974,"marketCap":450936898},{"date":"2022-03-25","current":-11.332448,"twenty":-25.602756,"median":44.47091,"eighty":93.831974,"marketCap":482796267},{"date":"2022-04-01","current":-11.620114,"twenty":-25.602756,"median":44.47091,"eighty":93.831974,"marketCap":495051732},{"date":"2022-04-08","current":-12.118467,"twenty":-25.602756,"median":44.47091,"eighty":93.831974,"marketCap":516283030},{"date":"2022-04-14","current":-13.030086,"twenty":-25.602756,"median":44.47091,"eighty":93.831974,"marketCap":555120770},{"date":"2022-04-22","current":-13.082758,"twenty":-25.602756,"median":44.47091,"eighty":93.831974,"marketCap":557364729},{"date":"2022-04-29","current":-11.956401,"twenty":-25.602756,"median":44.47091,"eighty":93.831974,"marketCap":509378543},{"date":"2022-05-06","current":-11.109607,"twenty":-25.602756,"median":44.423407,"eighty":93.831974,"marketCap":473302597},{"date":"2022-05-13","current":-6.838809,"twenty":-25.602756,"median":44.326499,"eighty":93.831974,"marketCap":429607173},{"date":"2022-05-20","current":-7.973013,"twenty":-25.602756,"median":44.264099,"eighty":93.831974,"marketCap":500856719},{"date":"2022-05-27","current":-8.009184,"twenty":-25.602756,"median":44.233827,"eighty":93.831974,"marketCap":503128915},{"date":"2022-06-03","current":-7.554469,"twenty":-25.602756,"median":44.233827,"eighty":93.831974,"marketCap":474564176},{"date":"2022-06-10","current":-7.099754,"twenty":-25.602756,"median":44.233827,"eighty":93.831974,"marketCap":445999438},{"date":"2022-06-17","current":-6.298835,"twenty":-25.602756,"median":44.233827,"eighty":93.831974,"marketCap":395686546},{"date":"2022-06-24","current":-7.46921,"twenty":-25.609501,"median":44.218628,"eighty":93.840828,"marketCap":469208288},{"date":"2022-07-01","current":-8.147407,"twenty":-25.609501,"median":44.029158,"eighty":93.840828,"marketCap":511811946},{"date":"2022-07-08","current":-8.125446,"twenty":-25.609501,"median":43.718314,"eighty":93.840828,"marketCap":510432399},{"date":"2022-07-15","current":-8.09961,"twenty":-25.609501,"median":43.551201,"eighty":93.840828,"marketCap":508809402},{"date":"2022-07-22","current":-8.202954,"twenty":-25.609501,"median":43.064392,"eighty":93.840828,"marketCap":515301388},{"date":"2022-07-29","current":-8.848856,"twenty":-25.609501,"median":42.112572,"eighty":93.840828,"marketCap":555876301},{"date":"2022-08-05","current":-8.94445,"twenty":-25.609501,"median":41.698422,"eighty":93.840828,"marketCap":561881388},{"date":"2022-08-12","current":-9.587738,"twenty":-25.609501,"median":41.211613,"eighty":93.840828,"marketCap":610125283},{"date":"2022-08-19","current":-9.160422,"twenty":-25.609501,"median":40.434173,"eighty":93.840828,"marketCap":582932617},{"date":"2022-08-26","current":-9.723353,"twenty":-25.609501,"median":-6.017222,"eighty":93.840828,"marketCap":618755292},{"date":"2022-09-02","current":-9.357448,"twenty":-25.609501,"median":-6.461603,"eighty":93.840828,"marketCap":595470553},{"date":"2022-09-09","current":-9.490504,"twenty":-25.609501,"median":-6.838809,"eighty":93.840828,"marketCap":603937731},{"date":"2022-09-16","current":-9.160422,"twenty":-25.609501,"median":-7.340029,"eighty":93.840828,"marketCap":582932617},{"date":"2022-09-23","current":-8.113882,"twenty":-25.609501,"median":-7.46921,"eighty":93.840828,"marketCap":516335008},{"date":"2022-09-30","current":-8.22391,"twenty":-25.609501,"median":-7.665564,"eighty":93.840828,"marketCap":523336712},{"date":"2022-10-07","current":-8.254615,"twenty":-25.609501,"median":-7.797328,"eighty":93.840828,"marketCap":525290676},{"date":"2022-10-14","current":-8.500258,"twenty":-25.609501,"median":-7.91359,"eighty":93.840828,"marketCap":540922389},{"date":"2022-10-21","current":-9.242303,"twenty":-25.609501,"median":-8.0066,"eighty":93.840828,"marketCap":588143188},{"date":"2022-10-28","current":-9.961319,"twenty":-25.609501,"median":-8.102194,"eighty":93.840828,"marketCap":633898513},{"date":"2022-11-04","current":-9.810351,"twenty":-25.609501,"median":-8.182285,"eighty":93.840828,"marketCap":624291523},{"date":"2022-11-11","current":-9.043105,"twenty":-25.609501,"median":-8.22391,"eighty":93.840828,"marketCap":613023068},{"date":"2022-11-18","current":-9.514501,"twenty":-25.609501,"median":-8.355252,"eighty":93.72897,"marketCap":644978525},{"date":"2022-11-25","current":-10.019568,"twenty":-25.609501,"median":-8.433729,"eighty":93.149414,"marketCap":679216516},{"date":"2022-12-02","current":-9.33893,"twenty":-25.609501,"median":-8.569345,"eighty":92.137422,"marketCap":633076748},{"date":"2022-12-09","current":-9.500071,"twenty":-25.609501,"median":-8.699842,"eighty":91.159402,"marketCap":644000297},{"date":"2022-12-16","current":-9.156144,"twenty":-25.609501,"median":-8.830771,"eighty":90.084372,"marketCap":620685856},{"date":"2022-12-23","current":-9.488045,"twenty":-25.609501,"median":-8.885027,"eighty":88.207549,"marketCap":643185107},{"date":"2022-12-30","current":-9.675642,"twenty":-25.609501,"median":-8.94445,"eighty":85.476822,"marketCap":655902075},{"date":"2023-01-06","current":-10.563117,"twenty":-25.609501,"median":-9.037601,"eighty":84.678021,"marketCap":716063115},{"date":"2023-01-13","current":-10.570332,"twenty":-25.609501,"median":-9.055512,"eighty":83.785101,"marketCap":716552229},{"date":"2023-01-20","current":-10.106151,"twenty":-25.609501,"median":-9.156144,"eighty":81.714404,"marketCap":685085886},{"date":"2023-01-27","current":-10.488559,"twenty":-25.609501,"median":-9.178333,"eighty":79.307707,"marketCap":711008936},{"date":"2023-02-03","current":-10.743498,"twenty":-25.609501,"median":-9.319066,"eighty":78.151242,"marketCap":728290969},{"date":"2023-02-10","current":-10.822865,"twenty":-25.609501,"median":-9.34374,"eighty":74.795751,"marketCap":733671225},{"date":"2023-02-17","current":-10.36109,"twenty":-25.609501,"median":-9.437539,"eighty":73.316501,"marketCap":702367919},{"date":"2023-02-24","current":-9.892099,"twenty":-25.609501,"median":-9.463995,"eighty":72.702367,"marketCap":670575499},{"date":"2023-03-03","current":-10.933499,"twenty":-25.435394,"median":-9.467475,"eighty":72.512607,"marketCap":741170975},{"date":"2023-03-10","current":-13.950056,"twenty":-24.971129,"median":-9.467475,"eighty":72.512607,"marketCap":668151872},{"date":"2023-03-17","current":-13.434525,"twenty":-24.508031,"median":-9.467475,"eighty":72.512607,"marketCap":643460014},{"date":"2023-03-24","current":-12.84047,"twenty":-23.901482,"median":-9.467475,"eighty":72.512607,"marketCap":615007144},{"date":"2023-03-31","current":-13.560847,"twenty":-23.734185,"median":-9.47776,"eighty":72.457404,"marketCap":649510337},{"date":"2023-04-06","current":-13.103356,"twenty":-23.276616,"median":-9.47776,"eighty":72.457404,"marketCap":627598357},{"date":"2023-04-14","current":-14.566675,"twenty":-22.927503,"median":-9.467475,"eighty":72.512607,"marketCap":697685448},{"date":"2023-04-21","current":-14.813567,"twenty":-22.372547,"median":-9.467475,"eighty":72.512607,"marketCap":709510626},{"date":"2023-04-28","current":-13.949443,"twenty":-21.607296,"median":-9.467475,"eighty":72.512607,"marketCap":668122506},{"date":"2023-05-05","current":-14.230003,"twenty":-21.372869,"median":-9.467475,"eighty":72.512607,"marketCap":681560207},{"date":"2023-05-11","current":-29.794637,"twenty":-21.500816,"median":-9.500071,"eighty":72.007154,"marketCap":784403414},{"date":"2023-05-19","current":-56.777451,"twenty":-22.064999,"median":-9.532539,"eighty":71.204986,"marketCap":1494779963},{"date":"2023-05-26","current":-32.844617,"twenty":-22.451972,"median":-9.621527,"eighty":70.195747,"marketCap":864700227},{"date":"2023-06-02","current":-33.036774,"twenty":-22.980041,"median":-9.652793,"eighty":69.862862,"marketCap":869759145},{"date":"2023-06-09","current":-35.484997,"twenty":-23.178195,"median":-9.670148,"eighty":68.90026,"marketCap":934213507},{"date":"2023-06-16","current":-36.089935,"twenty":-23.724334,"median":-9.72975,"eighty":67.226918,"marketCap":950139730},{"date":"2023-06-23","current":-36.68064,"twenty":-23.894858,"median":-9.77906,"eighty":63.86816,"marketCap":965691218},{"date":"2023-06-30","current":-38.082675,"twenty":-24.395292,"median":-9.853618,"eighty":61.559985,"marketCap":1002602582},{"date":"2023-07-07","current":-38.075558,"twenty":-24.746642,"median":-9.912543,"eighty":60.9286,"marketCap":1002415215},{"date":"2023-07-14","current":-35.976065,"twenty":-25.402745,"median":-10.017163,"eighty":60.493876,"marketCap":947141853},{"date":"2023-07-21","current":-36.780277,"twenty":-25.583596,"median":-10.097734,"eighty":60.038451,"marketCap":968314361},{"date":"2023-07-28","current":-36.68064,"twenty":-25.679487,"median":-10.317799,"eighty":59.150503,"marketCap":965691218},{"date":"2023-08-04","current":-37.136124,"twenty":-25.757224,"median":-10.457372,"eighty":56.817084,"marketCap":977682727},{"date":"2023-08-11","current":-222.079037,"twenty":-25.850737,"median":-10.495794,"eighty":54.293227,"marketCap":1145705754},{"date":"2023-08-18","current":-219.587884,"twenty":-25.917361,"median":-10.583761,"eighty":54.037177,"marketCap":1132853892},{"date":"2023-08-25","current":-232.080287,"twenty":-26.074388,"median":-10.682168,"eighty":53.63505,"marketCap":1197302203},{"date":"2023-09-01","current":-235.890287,"twenty":-26.135023,"median":-10.804827,"eighty":53.39322,"marketCap":1216957993},{"date":"2023-09-08","current":-229.662403,"twenty":-26.198767,"median":-10.842106,"eighty":53.156773,"marketCap":1184828336},{"date":"2023-09-15","current":-233.032787,"twenty":-26.325403,"median":-10.964765,"eighty":53.067365,"marketCap":1202216150},{"date":"2023-09-22","current":-217.353172,"twenty":-26.546851,"median":-11.360809,"eighty":52.793727,"marketCap":1121325015},{"date":"2023-09-29","current":-215.741249,"twenty":-26.616774,"median":-11.672785,"eighty":52.273601,"marketCap":1113009104},{"date":"2023-10-06","current":-214.788749,"twenty":-26.733499,"median":-11.954375,"eighty":50.934555,"marketCap":1108095156},{"date":"2023-10-13","current":-212.260961,"twenty":-27.062768,"median":-12.073899,"eighty":50.197317,"marketCap":1095054296},{"date":"2023-10-20","current":-209.95298,"twenty":-27.148708,"median":-12.393978,"eighty":49.856152,"marketCap":1083147423},{"date":"2023-10-27","current":-221.566153,"twenty":-27.192662,"median":-12.734037,"eighty":49.51106,"marketCap":1143059783},{"date":"2023-11-03","current":-229.186153,"twenty":-27.249765,"median":-13.028246,"eighty":49.395552,"marketCap":1182371362},{"date":"2023-11-10","current":74.513877,"twenty":-27.312133,"median":-13.082758,"eighty":49.346018,"marketCap":997070186},{"date":"2023-11-17","current":73.087774,"twenty":-27.312133,"median":-13.082758,"eighty":49.346018,"marketCap":977987503},{"date":"2023-11-24","current":73.943436,"twenty":-27.312133,"median":-13.082758,"eighty":49.346018,"marketCap":989437113},{"date":"2023-12-01","current":71.034186,"twenty":-27.312133,"median":-13.082758,"eighty":49.346018,"marketCap":950508440},{"date":"2023-12-08","current":69.493995,"twenty":-27.294941,"median":-13.056422,"eighty":49.358996,"marketCap":929899142},{"date":"2023-12-15","current":75.440844,"twenty":-27.312133,"median":-13.082758,"eighty":49.346018,"marketCap":1009473930},{"date":"2023-12-22","current":75.768847,"twenty":-27.312133,"median":-13.082758,"eighty":49.346018,"marketCap":1013862947},{"date":"2023-12-29","current":78.178961,"twenty":-27.329324,"median":-13.093057,"eighty":49.324601,"marketCap":1046112682},{"date":"2024-01-05","current":80.047156,"twenty":-27.346516,"median":-13.103356,"eighty":49.293085,"marketCap":1071110996},{"date":"2024-01-12","current":79.562281,"twenty":-27.346516,"median":-13.103356,"eighty":49.293085,"marketCap":1064622884},{"date":"2024-01-19","current":79.277061,"twenty":-27.363707,"median":-13.103356,"eighty":49.274727,"marketCap":1060806347},{"date":"2024-01-26","current":77.437388,"twenty":-27.346516,"median":-13.103356,"eighty":49.293085,"marketCap":1036189686},{"date":"2024-02-02","current":80.589075,"twenty":-27.346516,"median":-13.103356,"eighty":49.293085,"marketCap":1078362416},{"date":"2024-02-09","current":79.733413,"twenty":-27.346516,"median":-13.103356,"eighty":49.293085,"marketCap":1066912806},{"date":"2024-02-16","current":82.072222,"twenty":-27.346516,"median":-13.103356,"eighty":49.293085,"marketCap":1098208406},{"date":"2024-02-23","current":82.927884,"twenty":-27.346516,"median":-13.103356,"eighty":49.293085,"marketCap":1109658016},{"date":"2024-03-01","current":71.050516,"twenty":-27.329324,"median":-13.093057,"eighty":49.324601,"marketCap":1334257645},{"date":"2024-03-08","current":70.042559,"twenty":-27.329324,"median":-13.093057,"eighty":49.411858,"marketCap":1315329208},{"date":"2024-03-15","current":69.349588,"twenty":-27.329324,"median":-13.093057,"eighty":49.604826,"marketCap":1302315908},{"date":"2024-03-22","current":72.782944,"twenty":-27.329324,"median":-13.093057,"eighty":49.993478,"marketCap":1366790897},{"date":"2024-03-28","current":73.171427,"twenty":-27.329324,"median":-13.093057,"eighty":49.993478,"marketCap":1374086232},{"date":"2024-04-05","current":71.334004,"twenty":-27.346516,"median":-13.103356,"eighty":49.894276,"marketCap":1339581268},{"date":"2024-04-12","current":76.093972,"twenty":-27.346516,"median":-13.103356,"eighty":49.894276,"marketCap":1428968709},{"date":"2024-04-19","current":72.15018,"twenty":-27.346516,"median":-13.103356,"eighty":49.894276,"marketCap":1354908226},{"date":"2024-04-26","current":72.563552,"twenty":-27.329324,"median":-13.093057,"eighty":49.993478,"marketCap":1362670939},{"date":"2024-05-03","current":74.976751,"twenty":-27.329324,"median":-13.093057,"eighty":49.993478,"marketCap":1407988402},{"date":"2024-05-10","current":73.602568,"twenty":-27.329324,"median":-13.093057,"eighty":49.993478,"marketCap":1382182625},{"date":"2024-05-17","current":34.818397,"twenty":-27.329324,"median":-13.093057,"eighty":49.604826,"marketCap":1237689546},{"date":"2024-05-24","current":32.956538,"twenty":-27.329324,"median":-13.093057,"eighty":49.398269,"marketCap":1171506053},{"date":"2024-05-31","current":34.649137,"twenty":-27.329324,"median":-13.093057,"eighty":49.201225,"marketCap":1231672865},{"date":"2024-06-07","current":37.575695,"twenty":-27.329324,"median":-13.093057,"eighty":49.058538,"marketCap":1335703224},{"date":"2024-06-14","current":34.529017,"twenty":-27.346516,"median":-13.103356,"eighty":48.618246,"marketCap":1227402962},{"date":"2024-06-21","current":32.426918,"twenty":-27.363707,"median":-13.103356,"eighty":48.282592,"marketCap":1152679664},{"date":"2024-06-28","current":34.447117,"twenty":-27.368103,"median":-13.144326,"eighty":47.697066,"marketCap":1224491665},{"date":"2024-07-05","current":33.207698,"twenty":-27.368103,"median":-13.144326,"eighty":47.191366,"marketCap":1180434032},{"date":"2024-07-12","current":35.080476,"twenty":-27.368103,"median":-13.144326,"eighty":46.545561,"marketCap":1247005698},{"date":"2024-07-15","current":34.670977,"twenty":-27.368103,"median":-13.144326,"eighty":46.458973,"marketCap":1232449211},{"date":"2024-08-02","current":34.862077,"twenty":-27.415745,"median":-13.397035,"eighty":45.466555,"marketCap":1239242238},{"date":"2024-08-09","current":40.770114,"twenty":-27.415745,"median":-13.397035,"eighty":45.054829,"marketCap":1101404633},{"date":"2024-08-16","current":44.144143,"twenty":-27.415745,"median":-13.397035,"eighty":44.802371,"marketCap":1192554015},{"date":"2024-08-23","current":43.725098,"twenty":-27.415745,"median":-13.397035,"eighty":44.635258,"marketCap":1181233535},{"date":"2024-08-30","current":45.119504,"twenty":-27.415745,"median":-13.397035,"eighty":44.702103,"marketCap":1218903409},{"date":"2024-09-06","current":43.898496,"twenty":-27.415745,"median":-13.397035,"eighty":44.847419,"marketCap":1185917872},{"date":"2024-09-13","current":40.567817,"twenty":-27.415745,"median":-13.397035,"eighty":44.64979,"marketCap":1095939574},{"date":"2024-09-20","current":43.62395,"twenty":-27.415745,"median":-13.397035,"eighty":44.561555,"marketCap":1178501006},{"date":"2024-09-27","current":42.121171,"twenty":-27.415745,"median":-13.397035,"eighty":44.436175,"marketCap":1137903422},{"date":"2024-10-04","current":41.030211,"twenty":-27.415745,"median":-13.397035,"eighty":44.244358,"marketCap":1108431138},{"date":"2024-10-11","current":39.809202,"twenty":-27.415745,"median":-13.397035,"eighty":44.115243,"marketCap":1075445601},{"date":"2024-10-18","current":43.436102,"twenty":-27.415745,"median":-13.397035,"eighty":43.717962,"marketCap":1173426308},{"date":"2024-10-25","current":42.829211,"twenty":-27.415745,"median":-13.397035,"eighty":43.625385,"marketCap":1157031130},{"date":"2024-10-31","current":42.272893,"twenty":-27.415745,"median":-13.397035,"eighty":43.412983,"marketCap":1142002217},{"date":"2024-11-08","current":42.17897,"twenty":-27.424001,"median":-13.427697,"eighty":43.200989,"marketCap":1139464868},{"date":"2024-11-15","current":-162.206247,"twenty":-27.58243,"median":-13.5568,"eighty":43.200989,"marketCap":1150204495},{"date":"2024-11-22","current":-153.808198,"twenty":-27.970377,"median":-13.659856,"eighty":43.200989,"marketCap":1090653931},{"date":"2024-11-29","current":-157.580436,"twenty":-28.373227,"median":-13.949443,"eighty":43.137369,"marketCap":1117402873},{"date":"2024-12-06","current":-154.166148,"twenty":-28.925081,"median":-14.069148,"eighty":43.103757,"marketCap":1093192152},{"date":"2024-12-13","current":-155.735619,"twenty":-29.536697,"median":-14.163523,"eighty":42.711788,"marketCap":1104321274},{"date":"2024-12-20","current":-149.402664,"twenty":-29.809386,"median":-14.230003,"eighty":42.389937,"marketCap":1059414291},{"date":"2024-12-27","current":-152.816953,"twenty":-30.032369,"median":-14.259929,"eighty":42.268559,"marketCap":1083625012},{"date":"2025-01-03","current":-152.651745,"twenty":-30.59903,"median":-14.334745,"eighty":42.15296,"marketCap":1082453526},{"date":"2025-01-10","current":-149.127318,"twenty":-31.037127,"median":-14.458652,"eighty":42.12984,"marketCap":1057461814},{"date":"2025-01-17","current":-158.32387,"twenty":-31.451576,"median":-14.562095,"eighty":41.997389,"marketCap":1122674562},{"date":"2025-01-24","current":-161.600486,"twenty":-32.125167,"median":-14.692664,"eighty":41.686231,"marketCap":1145909044},{"date":"2025-01-31","current":-163.995995,"twenty":-32.844617,"median":-14.754511,"eighty":41.125579,"marketCap":1162895599},{"date":"2025-02-07","current":-165.730674,"twenty":-33.21612,"median":-14.853009,"eighty":40.589491,"marketCap":1175196207},{"date":"2025-02-14","current":-162.977215,"twenty":-34.503504,"median":-14.943931,"eighty":39.583785,"marketCap":1155671432},{"date":"2025-02-21","current":-164.298875,"twenty":-35.196049,"median":-15.022224,"eighty":36.693359,"marketCap":1165043324},{"date":"2025-02-28","current":-150.283771,"twenty":-35.482914,"median":-15.15608,"eighty":35.417904,"marketCap":1065662219},{"date":"2025-03-07","current":-66.935633,"twenty":-35.801182,"median":-15.325295,"eighty":34.853341,"marketCap":1239781788},{"date":"2025-03-14","current":-67.379677,"twenty":-36.374044,"median":-15.537445,"eighty":34.638217,"marketCap":1248006384},{"date":"2025-03-21","current":-70.553775,"twenty":-36.543996,"median":-15.658673,"eighty":34.391425,"marketCap":1306797020},{"date":"2025-03-28","current":-74.950366,"twenty":-36.777718,"median":-15.830414,"eighty":33.702373,"marketCap":1388230680},{"date":"2025-04-04","current":-74.873618,"twenty":-37.127584,"median":-15.916284,"eighty":33.489434,"marketCap":1386809145}],"updateTime":1743896537926}}}